Prialt (Ziconotide Acetate) Patent Expiration, LOE Window & CMS Spending
Prialt (Ziconotide Acetate) by Esteve Sa: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $58K 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Esteve Sa |
| FDA Application & Pathway | N021060 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Uncontested (0 AB Generics) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $58K |
| 2024 Medicare Part D Spend | $58K |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 9 WAC filings (max 26.4% 2-yr change) |